mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022

Euro Surveill. 2022 May;27(20):2200350. doi: 10.2807/1560-7917.ES.2022.27.20.2200350.

Abstract

For the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we estimated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using surveillance data. In the most vulnerable age group comprising individuals aged 65 years and more, VE against SARI COVID-19 was 95% (95% CI: 95-96%) for those vaccinated with three doses, in comparison to 82% (95% CI: 79-84%) for those vaccinated with two doses. Such levels of protection were maintained for at least 6 months.

Keywords: COVID-19; Omicron variant; Slovenia; mRNA vaccines; severe acute respiratory infection (SARI); surveillance; vaccine effectiveness.

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Hospitalization
  • Humans
  • RNA, Messenger
  • SARS-CoV-2* / genetics
  • Slovenia / epidemiology
  • Vaccines, Synthetic
  • mRNA Vaccines

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • Vaccines, Synthetic
  • mRNA Vaccines

Supplementary concepts

  • SARS-CoV-2 variants